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Abstract
Measurements of central venous oxygen saturation (ScvO2) have
been successfully used to guide haemodynamic therapy in critical
care. The efficacy of this approach in the treatment of severe
sepsis and septic shock has stimulated interest in the use of
ScvO2 to guide management in patients undergoing major surgery.
The physiological basis of ScvO2 measurement is complex. A
number of outstanding issues will need to be resolved before
incorporating ScvO2 measurement into routine practice. First, it is
not yet clear which value of ScvO2 should be targeted. Second,
there is some uncertainty as to which interventions are the most
effective for achieving the desired value of ScvO2 or how long this
value should be maintained. The study by The Collaborative Study
Group on Perioperative ScvO2 Monitoring published in this edition
of Critical Care may help provide answers to some of these
questions. Our understanding of ScvO2 measurement remains
limited, however, and the routine use of peri-operative ScvO2-
guided goal-directed therapy cannot be recommended until a large
randomised trial has confirmed the value of this approach.
The use of central venous saturation (ScvO2) to guide haemo-
dynamic management is an important and evolving aspect of
clinical practice. An observational study [1] published in this
issue of Critical Care has advanced our understanding of this
form of monitoring by exploring the association between
derangements in ScvO2 and complication rates after major
abdominal surgery. This study provides a detailed description
of peri-operative trends in ScvO2 and confirms the findings of
previous work which suggests that reductions in ScvO2 are
associated with increased post-operative complication rates
[2]. Although the study is relatively small, the robust multi-
centre approach and consistency with previous work support
the applicability of the findings.
The comparative simplicity of ScvO2 measurement makes
this an attractive technique. With the blood gas analysis
technology available in most institutions, intermittent ScvO2
monitoring can be performed in any patient with a central
venous catheter. However, it is not yet clear whether ScvO2
measurement through intermittent blood sampling is an
adequate alternative to continuous monitoring with a fibre-
optic catheter. Interest in ScvO2 measurement is not new,
and several reports have explored the physiology and clinical
significance of this parameter over the past 50 years [3]. Of
these, the work of Rivers and colleagues [4] has proved the
most influential. These authors used a ScvO2 value of 70%
as a target for goal-directed haemodynamic therapy (GDT) in
patients presenting to hospital with severe sepsis and septic
shock. They demonstrated that it may be possible to achieve
substantial mortality reductions without the need for complex
or invasive cardiac output monitoring technology. The
success of Rivers’ work and several trials of peri-operative
GDT indicates that the use of ScvO2 as a haemodynamic
goal may be equally valuable in surgical patients [5-8].
However, several questions must be considered before
embarking on an interventional trial of ScvO2-guided peri-
operative GDT. First, what treatments should be used to
achieve the target value for ScvO2? Second, which target
value is most appropriate? Finally, how long should the target
value be maintained? The study by the Collaborative Study
Group (CSG) is important because it sets out to address
some of these key questions. The value of ScvO2 in any given
patient reflects not only oxygen delivery but also oxygen
consumption. Reductions in ScvO2 may therefore reflect a
large number of acute changes in physiology including
hypoxia, shivering, anaesthesia, haemorrhage and myocardial
ischaemia [3]. The therapeutic approach to achieving the
target value may need to include more than simply
intravenous fluids and inotropic therapy. If a period of post-
operative sedation and invasive ventilation is required to
control oxygen consumption, would such an intervention be
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valid? Although the normal value of ScvO2 is often quoted as
70%, there are in fact few published data to confirm this,
either in healthy volunteers or in surgical patients [3].
Previous observational work shows that considerable
variations in ScvO2 may occur depending on the nature and
severity of the acute physiological disturbance. It would be
naive simply to accept this ‘normal’ value as being optimal in
every clinical situation.
The CSG researchers explored the relationship between
ScvO2 and post-operative complication rates. Their findings
suggest that a higher target value of 75% would be more
appropriate in patients undergoing major abdominal surgery.
This finding is consistent with the analysis of ScvO2 data
from a recent interventional trial of post-operative GDT [2].
However, both these studies have shown that large
decreases in ScvO2 occur immediately after surgery. It is
unclear whether such changes, which are more marked in
those patients who develop complications, relate pre-
dominantly to an increase in oxygen consumption, a decrease
in oxygen delivery or, more probably, a failure to increase
delivery to match increased consumption. What is more,
these observations raise the possibility that the most
appropriate goal for ScvO2 may vary during and after surgery.
The question of how long GDT should be continued remains
unanswered. Several recent successful GDT trials have
opted for short periods of early treatment lasting between 4
and 8 hours [4,6,7]. However, GDT has also been effective
when administered for periods of up to 24 hours [5,8].
As with any monitoring technology, ScvO2 is a double-edged
sword. Anecdotal evidence suggests that clinicians have a
limited understanding of the pitfalls associated with ScvO2
measurement, which may lead to a number of problems in
practice. For example, the aggressive targeting of too high a
value for ScvO2 may be harmful, particularly in the elderly.
The authors make an important point in suggesting that the
targeted value for ScvO2 should be modified for different
patient groups. In particular, the presence of cytopathic
hypoxia in septic patients may result in a high value of ScvO2
despite low oxygen delivery. Another consideration is that of
sampling site. Venous oxygen saturation differs between the
superior vena cava and the right atrium, and the value of
ScvO2 may therefore vary according to the position of the
catheter tip [3]. Despite the promising findings of this most
recent work, the routine peri-operative use of ScvO2-guided
GDT cannot be recommended until a large randomised trial
has confirmed the value of this approach.
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